Cargando…

Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma

Everolimus-associated cytomegalovirus colitis is very rare in cancer patients. We present a case of cytomegalovirus colitis that occurred on using everolimus in a 64-year-old male with metastatic renal cell carcinoma who received pazopanib, nivolumab, and everolimus treatments, respectively. Althoug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ismayilov, Rashad, Halit Aktepe, Oktay, Sardarova, Konul, Berk Leblebici, Can, Erman, Mustafa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Atatürk University School of Medicine 2022
Materias:	Letter to the Editor Medical Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634883/ https://www.ncbi.nlm.nih.gov/pubmed/35307634 http://dx.doi.org/10.5152/eurasianjmed.2022.20300

Ejemplares similares

The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma
por: AKTEPE1, Oktay Halit, et al.
Publicado: (2021)

Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19
por: Guven, Deniz Can, et al.
Publicado: (2020)

Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease
por: Yildirim, Hasan Cagri, et al.
Publicado: (2022)

Severe immune thrombocytopenia induced by nivolumab in a patient with metastatic renal cell carcinoma
por: Hata, Shinro, et al.
Publicado: (2020)

Everolimus in Invasive Malignant Renal Epithelioid Angiomyolipoma
por: Guo, Gang, et al.
Publicado: (2021)

Complete response to nivolumab for metastatic renal cell carcinoma on hemodialysis patient; a case report
por: Ito, Akito, et al.
Publicado: (2019)

The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy
por: Guven, Deniz Can, et al.
Publicado: (2022)

A case report of nivolumab-induced myasthenia gravis and myositis in a metastatic renal cell carcinoma patient
por: Nakanishi, Shotaro, et al.
Publicado: (2019)

Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
por: Stoff, Ronen, et al.
Publicado: (2022)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kwok, Christopher, et al.
Publicado: (2023)

Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma
por: Billon, Emilien, et al.
Publicado: (2019)

Nivolumab drug holiday in patients treated for metastatic renal cell carcinoma: A real-world, single-centre experience
por: Bimbatti, Davide, et al.
Publicado: (2022)

Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations
por: Vázquez-Montero, Lucía, et al.
Publicado: (2023)

Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy
por: Schwab, Katjana S., et al.
Publicado: (2019)

Ipilimumab and Nivolumab-Induced Colitis in a Patient With Recurrent Metastatic Melanoma
por: Moein, Hamid-Reza, et al.
Publicado: (2021)

Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards
por: Guven, Deniz C, et al.
Publicado: (2021)

Nivolumab for Metastatic Urothelial Cancer in a Renal Allograft Recipient With Subsequent Graft Rejection and Treatment Complete Remission: A Case Report
por: Chen, Didi, et al.
Publicado: (2021)

Prognostic Impact of Baseline Neutrophil-to-Eosinophil Ratio in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Therapy in Second or Later Lines
por: Gil, Lucia, et al.
Publicado: (2022)

Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
por: Kim, Jwa Hoon, et al.
Publicado: (2022)

Nivolumab and immune‐mediated colitis
por: Walker, Heather, et al.
Publicado: (2019)

Everolimus in Anaplastic Thyroid Cancer: A Case Series
por: Harris, Ethan J., et al.
Publicado: (2019)

Effectiveness of everolimus for sporadic renal angiomyolipoma with inferior vena cava thrombus: A case report
por: Iwatani, Kosuke, et al.
Publicado: (2023)

Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factor-kappa B (NF-κB) pathway
por: AKTEPE, Oktay Halit, et al.
Publicado: (2021)

Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?
por: Ucar, Gokhan, et al.
Publicado: (2020)

Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report
por: Reiter, Selina, et al.
Publicado: (2023)

Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
por: Wang, Ye, et al.
Publicado: (2022)

The Complete Response of a Renal Cell Carcinoma Metastatic to Brain, Lungs, and Liver to Second-Line Nivolumab: A Case Report
por: Haghpanah, Mahsa, et al.
Publicado: (2022)

Case Report: Complete Response of Recurrent and Metastatic Cystadenocarcinoma of the Parotid Gland With a Single Course of Combined Nivolumab and Ipilimumab Therapy
por: Nakamura, Yoshiyuki, et al.
Publicado: (2021)

Favorable Response of Metastatic Hepatocellular Carcinoma to Treatment with Trans-arterial Radioembolization Followed by Sorafenib and Nivolumab
por: Adcock, Charles S, et al.
Publicado: (2019)

Everolimus/nivolumab: Severe acute respiratory syndrome Coronavirus-2 infection: case report
Publicado: (2021)

The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Everolimus in the Treatment of Metastatic Breast Cancer
por: Royce, Melanie E, et al.
Publicado: (2015)

Immunological effects of everolimus in patients with metastatic renal cell cancer
por: Huijts, Charlotte M, et al.
Publicado: (2017)

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
por: Rossetti, Sabrina, et al.
Publicado: (2017)

Durable Complete Radiological Response to Nivolumab in Two Heavily Pretreated Western Elderly Patients With Metastatic Gastric Cancer: A Case Report
por: Tirino, Giuseppe, et al.
Publicado: (2020)

Efficacy of Everolimus for Treating Renal Angiomyolipoma with Inferior Vena Cava Thrombus Associated with Tuberous Sclerosis: A Case Report
por: Ikarashi, Daiki, et al.
Publicado: (2017)

Defining the Magnetic Resonance Features of Renal Lesions and Their Response to Everolimus in a Transgenic Mouse Model of Tuberous Sclerosis Complex
por: Agarwal, Shubhangi, et al.
Publicado: (2022)

Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer
por: Fakih, M., et al.
Publicado: (2010)

Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report
por: Ruiz-Bañobre, Juan, et al.
Publicado: (2016)

Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus
por: Sciammarella, Concetta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l7p8658kqhsdmpfthio88na90h